HomeCompareDMTK vs PLD

DMTK vs PLD: Dividend Comparison 2026

DMTK yields 2127.66% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DMTK wins by $17707088686.87M in total portfolio value
10 years
DMTK
DMTK
● Live price
2127.66%
Share price
$0.09
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$17707088693.38M
Annual income
$16,208,512,607,342,262.00
Full DMTK calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — DMTK vs PLD

📍 DMTK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDMTKPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DMTK + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DMTK pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DMTK
Annual income on $10K today (after 15% tax)
$180,851.06/yr
After 10yr DRIP, annual income (after tax)
$13,777,235,716,240,922.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, DMTK beats the other by $13,777,235,711,772,952.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DMTK + PLD for your $10,000?

DMTK: 50%PLD: 50%
100% PLD50/50100% DMTK
Portfolio after 10yr
$8853544349.94M
Annual income
$8,104,256,306,299,349.00/yr
Blended yield
91.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

DMTK
Analyst Ratings
3
Buy
4
Hold
Consensus: Hold
Price Target
$7.50
+7878.7% upside vs current
Range: $7.50 — $7.50
Altman Z
-8.4
Piotroski
4/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DMTK buys
0
PLD buys
0
No recent congressional trades found for DMTK or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDMTKPLD
Forward yield2127.66%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$17707088693.38M$6.50M
Annual income after 10y$16,208,512,607,342,262.00$5,256,436.18
Total dividends collected$17601219228.91M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldBuy
Analyst price target$7.50$136.00

Year-by-year: DMTK vs PLD ($10,000, DRIP)

YearDMTK PortfolioDMTK Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$223,466$212,765.96$11,255$555.24+$212.2KDMTK
2$4,682,655$4,443,546.58$13,062$1,018.59+$4.67MDMTK
3$92,031,981$87,021,539.62$15,903$1,926.67+$92.02MDMTK
4$1,696,889,334$1,598,415,114.79$20,839$3,823.32+$1696.87MDMTK
5$29,359,261,977$27,543,590,390.03$30,464$8,166.08+$29359.23MDMTK
6$476,792,027,971$445,377,617,654.91$52,054$19,457.30+$476791.98MDMTK
7$7,269,883,644,738$6,759,716,174,809.65$109,886$54,188.93+$7269883.53MDMTK
8$104,104,693,867,782$96,325,918,367,911.80$304,030$186,451.18+$104104693.56MDMTK
9$1,400,538,398,162,041$1,289,146,375,723,514.20$1,166,125$840,813.32+$1400538397.00MDMTK
10$17,707,088,693,375,648$16,208,512,607,342,262.00$6,504,190$5,256,436.18+$17707088686.87MDMTK

DMTK vs PLD: Complete Analysis 2026

DMTKStock

DermTech, Inc., a molecular diagnostic company, develops and markets novel non-invasive genomics tests to diagnosis skin cancer, inflammatory diseases, and aging-related conditions in the United States. It offers DermTech Melanoma Test (DMT), a gene expression test that enhances early detection of genomic atypia and helps rule out melanoma and the need for a surgical biopsy of atypical pigmented lesions. The company also provides adhesive skin sample collection kits, as well as gene expression assays for the Th1, Th2, IFN-gamma, and Th17 inflammatory pathways. In addition, it is developing UV damage DNA risk assessment products, as well as non-melanoma skin cancer diagnostic and cutaneous T-cell lymphoma rule out test products, as well as offering health-related and information services through electronic information and telecommunication technologies. The company sells its products primarily to pathology and oncology practitioners. DermTech, Inc. is headquartered in La Jolla, California.

Full DMTK Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this DMTK vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DMTK vs SCHDDMTK vs JEPIDMTK vs ODMTK vs KODMTK vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.